In a previous study in which we analyzed colorectal cancer tissue for their TP53 mutation and expression statuses using next-generation sequencing and immunohistochemistry, respectively, and correlated them, we found that p53 expression groups differed significantly in the frequency and type of TP53 mutations; nonsynonymous single-nucleotide variant rate was 80%, 12%, and 2% in p53 group 3, 2, and 1, respectively, whereas p53 group 0 was featured with stop-gain mutations (38%) and indels (15%) [18]. The gene discussed is TP53; the disease is colorectal cancer.